Merve Cin

Dr. Merve Cin

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2018 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
ÖGÖzgecan Gündoğar
Özgecan Gündoğar
EKELİFE KIMILOĞLU
ELİFE KIMILOĞLU
NKNeslihan Komut
Neslihan Komut
MCMerve Cin
Merve Cin
SBSibel Bektaş
Sibel Bektaş
NENusret Erdoğan
Nusret Erdoğan
Appendiceal mucinous neoplasms constitute a diagnostic spectrum ranging from adenoma to mucinous adenocarcinoma. To date, many classification systems have been proposed to reflect the histomorphological diversity of neoplasms in this range and their clinical correspondence, and also to form a common terminology between the pathologist and clinicians. The aim of this review is to provide an updated perspective on the pathological features of appendiceal mucinous neoplasms. Using the 2016 Modified Delphi Consensus Protocol (Delphi) and the Eighth Edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 19 cases presented from June 2011 to December 2016 were evaluated and diagnosed with appendiceal mucinous neoplasia. According to the Delphi, non-carcinoid epithelial tumours of the appendix were categorized in eight histomorphological architectural groups. These groups are adenoma, serrated polyp, low-grade appendiceal mucinous neoplasm, high-grade appendiceal mucinous neoplasm, mucinous adenocarcinoma, poorly-differentiated adenocarcinoma with signet-ring, signet-ring cell carcinoma and adenocarcinoma. The most common symptom was right lower quadrant pain. The median age of these cases was 60±15 years. There was a preponderance of females (F/M: 15/4). In our re-evaluation, six cases were diagnosed as serrated polyp. There were 11 cases in the LAMN group and two cases in the mucinous adenocarcinoma group. Using the Delphi and the AJCC manual, there were many changes in the classification, evaluation and treatment of appendiceal mucinous neoplasms. These classification systems have facilitated the compatibility and communication of clinicians and pathologists and have guided clinicians on treatment methods. Cite this article as: Gündoğar Ö, Kımıloğlu E, Komut N, et al. Evaluation of appendiceal mucinous neoplasms with a new classification system and literature review. Turk J Gastroenterol 2018; 29: 532-42.

12 October 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
MCMerve Cin
Merve Cin
AİAyşenur Akyıldız İğdem
Ayşenur Akyıldız İğdem
SBSibel Bektaş
Sibel Bektaş
ÖGÖzgecan Gündoğar
Özgecan Gündoğar
SCSelçuk Cin
Selçuk Cin
BÇBuğra Çetin
Buğra Çetin
Background/Objectives: Bladder cancer, predominantly urothelial carcinoma, is an important malignancy of the urinary system. Despite the same histologic grade and stage, some patients seem to have a worse prognosis. In this context, the epithelial–mesenchymal transition (EMT), characterized by the loss of E-cadherin and gain of vimentin expression, is an important process in tumor progression. Galectin-3, a lactose-binding protein involved in various cellular processes, has been associated with increased tumor cell migration, invasion, and treatment resistance. Methods: In this study, 223 bladder cancer cases were examined, and E-cadherin, vimentin, and galectin-3 expression was evaluated by immunohistochemical staining in tumor budding areas and invasive components. These markers were also correlated with clinicopathological parameters, including tumor grade and stage. Results: The results indicated a significant decrease in E-cadherin expression and an increase in vimentin staining in higher-grade and higher-stage tumors, supporting EMT involvement. Galectin-3 expression was notably higher in T1 high-grade tumors but decreased in T2 stage tumors. Despite this, no significant correlation was found between galectin-3 and E-cadherin or vimentin, suggesting a complex role of galectin-3 in EMT. Conclusions: High galectin-3 expression in T1 high-grade tumors highlights its potential role in early tumor progression and as a therapeutic target. However, the decrease in its expression in advanced stages underscores the need for further research to understand its multifaceted involvement in bladder cancer. These findings suggest that while galectin-3 may contribute to the EMT and early tumor progression, its exact role and potential as a therapeutic target require more detailed investigation.


1 January 2026 in Journal of Clinical and Analytical Medicine
Verified
Journal Article
Closed access
BTBahaeddin Tapkan
Bahaeddin Tapkan
EŞEsin Şair
Esin Şair
MCMerve Cin
Merve Cin
SISaid İnCir
Said İnCir
SASoykan Arıkan
Soykan Arıkan

1 February 2021 in Molecular Imaging and Radionuclide Therapy
Verified
Journal Article
Open access
EAEsra Arslan
Esra Arslan
TATAMER AKSOY
TAMER AKSOY
MCMerve Cin
Merve Cin
CÇCoşkun Çakır
Coşkun Çakır
FTFadime Didem Can Trabulus
Fadime Didem Can Trabulus
TÇTevfik Fikret Çermik
Tevfik Fikret Çermik
A 67-year-old male patient had undergone total gastrectomy and Roux-en-Y eso-jejunostomy 3 years ago for the treatment of tubular adenocarcinoma located at the corpus of the stomach. The patient was diagnosed with Gleason score 8 (4+4) metastatic prostate cancer during the follow-up period and received hormone therapy. Owing to his elevated prostate-specific antigen levels (77 ng/mL), his clinician referred him gallium-68 (Ga-68) prostate-specific membrane antigen 11 (PSMA) positron emission tomography/computed tomography (PET/CT) for restaging. PET/CT showed multiple Ga-68 PSMA receptor-positive skeletal lesions and linear PSMA activity at the eso-jejunostomy junction. He was then referred to undergo (18)fluorine-fluorodeoxyglucose (F-18-FDG) PET/CT to screen for gastric carcinoma recurrence. PET/CT images demonstrated no F-18-FDG avid lesion. However, endoscopy and biopsy performed with samples from the eso-jejunostomy junction revealed superficial benign squamous epithelial fragments.